From protocol amendments to participant recruitment and retention, the impact of COVID-19 could be enormous. What can you do to minimize the disruption to your ongoing, or upcoming, clinical trial? Our panel of experts from NYU Langone Medical Center and WCG discuss ways to reduce the impact of this pandemic on your studies to keep them on track.
Other content in this Stream
Jonca Bull, MD: We Should Not Be Surprised — COVID-19 Disparities Lay Bare What’s Been There All Along
In this episode, former Assistant FDA Commissioner Jonca Bull, MD, discusses racial disparities in healthcare, how COVID-19 has made them impossible to ignore, and how this highlights the need for div
Dr. Edith Mitchell, MD: COVID-19 Doesn't Play Fair — What We Need to Understand About Racial Disparities
Dr. David Fajgenbaum, MD, Castleman’s Disease Survivor, Facing COVID-19 with Research, Action, and Hope
COVID-19 Insights from Former FDA Commissioner, Scott Gottlieb, MD
The coronavirus has spread beyond the point of containment, and there’s a looming shortage of personal protective equipment. Hear insights from former FDA Commissioner, Scott Gottlieb, MD.
COVID-19 Preparedness for Health Care Institutions with Dr. Paul Biddinger of Massachusetts General Hospital
Save the Data. Protect the Patients. Prepare for What Comes Next: Remote Clinical Research Coordinators
Infectious Disease Challenge Studies: Ethical Issues in Causing Disease for Medical Knowledge
1:01:03PART 12: Public Awareness of Clinical Research and the Path To Diversity in Clinical Trials
59:47PART 11: The Impact of COVID-19 on Oncology Research: Immediate and Long-term Effects
1:00:51PART 10: Unique Challenges and Opportunities for Emerging Biopharma Companies with Focused Pipelines
